Can I Take Ashwagandha with MK-677 (Ibutamoren)?

What Are These Two Compounds and Why Do People Stack Them?

MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that stimulates pulsatile release of growth hormone (GH) and, downstream, insulin-like growth factor 1 (IGF-1). It is not FDA-approved for any clinical indication. Most current use is off-label, by athletes, bodybuilders, and biohackers pursuing muscle mass, sleep quality, or recovery. The compound was originally developed by a pharmaceutical sponsor for muscle wasting and GH deficiency and reached mid-stage clinical trials before that development program ended.

Ashwagandha (Withania somnifera) is an Ayurvedic herb standardized to withanolide content. It has been studied in randomized trials for stress reduction, cortisol lowering, and, in some populations, testosterone and thyroid hormone changes. Unlike MK-677, it is sold over the counter as a dietary supplement under U.S. law, which means it has not gone through FDA drug-approval review, but it has an accumulated body of short-term (mostly up to 12 weeks) clinical trial safety data at typical extract doses.

People combine the two because their claimed benefits seem complementary: MK-677 targets the GH/IGF-1 axis, ashwagandha targets stress hormones and, in some studies, androgens. The overlap is real, but it runs in more directions than "complementary" implies, which is the reason this page exists.

How MK-677 Works

MK-677 mimics ghrelin at the GH secretagogue receptor (GHSR-1a), triggering pituitary somatotroph cells to release GH in a pulsatile pattern. A 2-year randomized, placebo-controlled trial in older adults (N=65) found that 25 mg/day oral MK-677 raised IGF-1 by roughly 40% from baseline, increased fat-free mass, and also produced a small but statistically significant rise in fasting glucose and HbA1c compared with placebo [1]. GH pulses are largest at night, which is why most protocols dose MK-677 30 to 60 minutes before sleep.

How Ashwagandha Works

Ashwagandha's withanolides are thought to act on the hypothalamic-pituitary-adrenal (HPA) axis, and several trials report reduced serum cortisol with supplementation. A double-blind, placebo-controlled trial of a high-concentration root extract (KSM-66, N=64) found that 300 mg twice daily reduced serum cortisol by 27.9% over 60 days versus 7.9% with placebo (P<0.001) [2]. Separate small trials report changes in testosterone and thyroid hormones in specific populations, discussed by axis below, the population each trial was conducted in matters for how far you can extend the result.

Evidence-Status Interaction Assessment

There is no published trial of ashwagandha plus MK-677. The table below separates what each compound has actually shown on its own, what is mechanistically plausible when you put the two together, what remains unestablished, and what a clinician or pharmacist should check before you rely on this stack.

Is the MK-677 and Ashwagandha Interaction Pharmacokinetic or Pharmacodynamic?

The interaction, to the extent it exists, is pharmacodynamic, overlapping hormonal effects, rather than pharmacokinetic. There is no published evidence that ashwagandha meaningfully alters the metabolism of MK-677 or vice versa.

No Documented Pharmacokinetic Overlap

MK-677's oral absorption does not depend heavily on CYP3A4 metabolism at the doses studied (10 to 25 mg). Ashwagandha's withanolides are metabolized primarily through glucuronidation and sulfation. Because MK-677 is not FDA-approved, no formal drug-interaction study has been conducted or published for it with any supplement, ashwagandha included. That is an absence of data, not a demonstrated absence of interaction.

Where the Real Overlap Lives

See the assessment table above for the axis-by-axis breakdown. The two most actionable overlaps are the thyroid axis, because the two compounds could push a thyroid panel in different directions at once, and fasting glucose, because MK-677's glucose-raising effect is well replicated and ashwagandha's offsetting effect comes from studies in a different population (see below).

Cortisol Modulation: Additive Benefit or Risk?

Ashwagandha's cortisol-lowering effect is one of its better-replicated findings, including the 27.9% reduction at 60 days cited above [2]. Claims that MK-677 also independently lowers cortisol are common in online discussion of the compound, but the pivotal 2-year MK-677 trial in older adults did not report cortisol as a primary interaction finding of the kind described in forum posts [1]. Treat any specific claim about MK-677's cortisol effect as unverified until you can check it against the full trial data, rather than assuming it compounds with ashwagandha's effect.

The GH-Cortisol Axis

Cortisol is a physiological antagonist of GH signaling: chronically high cortisol suppresses GH secretion. This makes the theory that lowering cortisol could make MK-677's GH secretagogue action more effective mechanistically plausible. It has not been tested in a human trial that combines the two agents.

When Cortisol Suppression Goes Too Far

Cortisol below the normal range can impair immune response, reduce blood pressure regulation, and cause fatigue that resembles adrenal insufficiency. This is unlikely at standard doses (300 to 600 mg ashwagandha extract) in a healthy adult, but the risk is not zero in someone already under significant physiological stress, using other cortisol-lowering agents, or with an underlying adrenal disorder. A morning serum cortisol drawn before supplementation is a reasonable precaution if you plan to run this stack for more than 8 weeks.

Sleep Quality: One Area Where This Stack May Perform Well

MK-677 increased slow-wave sleep (SWS) in a small crossover trial: a single 25 mg dose raised SWS compared with placebo in young adults, though the sample was very small (N=9) [5]. Ashwagandha improved Pittsburgh Sleep Quality Index (PSQI) scores relative to placebo in a double-blind trial of adults with insomnia and anxiety (N=60) [6]. The two mechanisms proposed, ghrelin-receptor-driven GH pulsing and GABA-A receptor modulation, are distinct enough that an additive sleep benefit is plausible. No trial has tested the combination directly, and the MK-677 sleep data in particular comes from a very small study that should not be over-generalized.

Insulin Sensitivity: The Most Important Safety Concern

MK-677's most clinically significant and best-replicated adverse effect is a rise in fasting glucose and HbA1c, seen in its pivotal 2-year trial [1]. The trial's authors cautioned against use in people with impaired glucose tolerance.

Ashwagandha's Modest Glucose-Lowering Effect

A systematic review and meta-analysis of ashwagandha trials in diabetes reported a reduction in fasting blood glucose compared with placebo [7]. Most of the trials in that meta-analysis enrolled people with diabetes or prediabetes, not the metabolically healthy adults who typically use MK-677, so the magnitude of benefit in a non-diabetic MK-677 user is not established and should not be assumed to fully offset MK-677's glucose-raising effect.

Practical Implication

Fasting glucose should be checked at baseline, at 8 weeks, and periodically during ongoing MK-677 use regardless of ashwagandha co-use. The American Diabetes Association defines the prediabetes range as a fasting glucose of 100 to 125 mg/dL [8]; anyone in or above that range should talk to a physician before starting MK-677.

Doses Used in Published Trials

The information below describes doses studied in clinical trials or commonly reported in off-label use, not a personalized recommendation. MK-677 is not FDA-approved, and neither compound's dosing should be decided from an article rather than a clinician who knows your health history.

• MK-677: Studied at 10 to 25 mg orally, most often once nightly given GH pulses peak during sleep. Trials and off-label protocols often start lower (around 10 mg) for the first weeks to assess tolerability, particularly water retention and appetite stimulation.
• Ashwagandha: The trials with the largest reported effects used 300 mg twice daily or 600 mg once daily of a standardized extract (KSM-66 or Sensoril, generally around 5% withanolides).
• Duration: Published MK-677 trials have run up to 2 years in the pivotal study, though most off-label use is shorter. Ashwagandha RCTs generally run 8 to 12 weeks; safety data beyond that window is limited.
• Monitoring cadence: Baseline labs before starting, repeat around 8 weeks, and periodically thereafter, see the checklist below.

Who Should Get Individualized Medical Guidance Before Combining These

• Active thyroid disease (Hashimoto's, Graves') or anyone on thyroid medication.
• Prediabetes (fasting glucose 100 to 125 mg/dL) or type 2 diabetes.
• Pregnancy or breastfeeding: ashwagandha is contraindicated in pregnancy per NIH's Office of Dietary Supplements [9], and MK-677 has no human reproductive safety data.
• Autoimmune conditions: ashwagandha may stimulate immune activity in ways that are not well characterized in people with active autoimmune disease [9].
• Anyone under 18: neither compound has pediatric safety data.

What Guidelines and Reference Sources Say

The Endocrine Society's clinical practice guideline on adult GH deficiency emphasizes that GH-directed therapy should only follow comprehensive biochemical confirmation of deficiency, and its scope predates the off-label use of GH secretagogues like MK-677 in people without diagnosed GH deficiency, the guideline does not address ashwagandha or supplement co-use at all [10].

We are not able to verify a specific 2023 professional-association position statement on ashwagandha dosing that appeared in an earlier draft of this page; it has been removed rather than presented as sourced. If your organization has a citable position statement on ashwagandha safety thresholds, it should be added back with a direct link.

No guideline body has evaluated the MK-677-plus-ashwagandha combination, because no direct combination trial exists. Absence of a reported safety signal in case reports is not evidence of safety, it mostly reflects that almost no one has looked.

Monitoring Checklist Before and During the Stack

Before starting:

• Fasting glucose and HbA1c
• IGF-1 (morning, fasted)
• TSH, free T3, free T4
• Total and free testosterone (men)
• AM serum cortisol (drawn before 9 AM, before any supplements)
• Comprehensive metabolic panel (CMP)

Around 8 weeks:

• Repeat all of the above
• Blood pressure (MK-677 can increase fluid retention and transiently affect BP)
• Note sleep quality, appetite changes, and joint discomfort (reported MK-677 side effects)

Reasons to stop and consult a physician:

• Fasting glucose above 126 mg/dL on two separate readings
• TSH outside roughly 0.4 to 4.5 mIU/L (use your lab's reference range)
• Symptoms of cortisol excess (central weight gain, new stretch marks, hypertension) or cortisol deficiency (fatigue, hypotension, hypoglycemia)
• New paresthesias in hands or feet (carpal tunnel has been reported with MK-677 at 25 mg)

Summary of the Interaction Profile

Evidence verification note for editorial review: an automated primary-source search for this topic returned only FDA labels for unrelated drugs and general JAMA articles with no clear connection to ibutamoren or ashwagandha; none is cited above because none could be confirmed to support a specific claim in this article. Before publication, a manual check of a clinical interaction database (e.g., Natural Medicines or Lexicomp) and a targeted PubMed search for "ibutamoren" plus "ashwagandha" or "Withania somnifera" is recommended to confirm no direct combination study has since been published.